Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT

普瑞巴林 医学 度洛西汀 神经病理性疼痛 耐受性 物理疗法 随机对照试验 不利影响 简短疼痛清单 生活质量(医疗保健) 医院焦虑抑郁量表 疼痛量表 焦虑 麻醉 内科学 慢性疼痛 精神科 替代医学 病理 护理部
作者
Solomon Tesfaye,Gordon Sloan,Jennifer Petrie,David White,Mike Bradburn,Tracey Young,Satyan Rajbhandari,Sanjeev Sharma,Gerry Rayman,Ravikanth Gouni,Uazman Alam,Steven A. Julious,Cindy Cooper,Amanda Loban,Katie Sutherland,Rachel Glover,Simon Waterhouse,Emily Turton,Michelle Horspool,Rajiv Gandhi
出处
期刊:Health Technology Assessment [NIHR Journals Library]
卷期号:26 (39): 1-100 被引量:14
标识
DOI:10.3310/rxuo6757
摘要

Background The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have not been directly compared. Objectives To determine the most clinically beneficial, cost-effective and tolerated treatment pathway for diabetic peripheral neuropathic pain. Design A randomised crossover trial with health economic analysis. Setting Twenty-one secondary care centres in the UK. Participants Adults with diabetic peripheral neuropathic pain with a 7-day average self-rated pain score of ≥ 4 points (Numeric Rating Scale 0–10). Interventions Participants were randomised to three commonly used treatment pathways: (1) amitriptyline supplemented with pregabalin, (2) duloxetine supplemented with pregabalin and (3) pregabalin supplemented with amitriptyline. Participants and research teams were blinded to treatment allocation, using over-encapsulated capsules and matching placebos. Site pharmacists were unblinded. Outcomes The primary outcome was the difference in 7-day average 24-hour Numeric Rating Scale score between pathways, measured during the final week of each pathway. Secondary end points included 7-day average daily Numeric Rating Scale pain score at week 6 between monotherapies, quality of life (Short Form questionnaire-36 items), Hospital Anxiety and Depression Scale score, the proportion of patients achieving 30% and 50% pain reduction, Brief Pain Inventory – Modified Short Form items scores, Insomnia Severity Index score, Neuropathic Pain Symptom Inventory score, tolerability (scale 0–10), Patient Global Impression of Change score at week 16 and patients’ preferred treatment pathway at week 50. Adverse events and serious adverse events were recorded. A within-trial cost–utility analysis was carried out to compare treatment pathways using incremental costs per quality-adjusted life-years from an NHS and social care perspective. Results A total of 140 participants were randomised from 13 UK centres, 130 of whom were included in the analyses. Pain score at week 16 was similar between the arms, with a mean difference of –0.1 points (98.3% confidence interval –0.5 to 0.3 points) for duloxetine supplemented with pregabalin compared with amitriptyline supplemented with pregabalin, a mean difference of –0.1 points (98.3% confidence interval –0.5 to 0.3 points) for pregabalin supplemented with amitriptyline compared with amitriptyline supplemented with pregabalin and a mean difference of 0.0 points (98.3% confidence interval –0.4 to 0.4 points) for pregabalin supplemented with amitriptyline compared with duloxetine supplemented with pregabalin. Results for tolerability, discontinuation and quality of life were similar. The adverse events were predictable for each drug. Combination therapy (weeks 6–16) was associated with a further reduction in Numeric Rating Scale pain score (mean 1.0 points, 98.3% confidence interval 0.6 to 1.3 points) compared with those who remained on monotherapy (mean 0.2 points, 98.3% confidence interval –0.1 to 0.5 points). The pregabalin supplemented with amitriptyline pathway had the fewest monotherapy discontinuations due to treatment-emergent adverse events and was most commonly preferred (most commonly preferred by participants: amitriptyline supplemented with pregabalin, 24%; duloxetine supplemented with pregabalin, 33%; pregabalin supplemented with amitriptyline, 43%; p = 0.26). No single pathway was superior in cost-effectiveness. The incremental gains in quality-adjusted life-years were small for each pathway comparison [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin –0.002 (95% confidence interval –0.011 to 0.007) quality-adjusted life-years, amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline –0.006 (95% confidence interval –0.002 to 0.014) quality-adjusted life-years and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline 0.007 (95% confidence interval 0.0002 to 0.015) quality-adjusted life-years] and incremental costs over 16 weeks were similar [amitriptyline supplemented with pregabalin compared with duloxetine supplemented with pregabalin −£113 (95% confidence interval −£381 to £90), amitriptyline supplemented with pregabalin compared with pregabalin supplemented with amitriptyline £155 (95% confidence interval −£37 to £625) and duloxetine supplemented with pregabalin compared with pregabalin supplemented with amitriptyline £141 (95% confidence interval −£13 to £398)]. Limitations Although there was no placebo arm, there is strong evidence for the use of each study medication from randomised placebo-controlled trials. The addition of a placebo arm would have increased the duration of this already long and demanding trial and it was not felt to be ethically justifiable. Future work Future research should explore (1) variations in diabetic peripheral neuropathic pain management at the practice level, (2) how OPTION-DM (Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus) trial findings can be best implemented, (3) why some patients respond to a particular drug and others do not and (4) what options there are for further treatments for those patients on combination treatment with inadequate pain relief. Conclusions The three treatment pathways appear to give comparable patient outcomes at similar costs, suggesting that the optimal treatment may depend on patients’ preference in terms of side effects. Trial registration The trial is registered as ISRCTN17545443 and EudraCT 2016-003146-89. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in Health Technology Assessment ; Vol. 26, No. 39. See the NIHR Journals Library website for further project information.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
詹詹发布了新的文献求助10
2秒前
YAXUESUN完成签到 ,获得积分10
3秒前
王WWWWWWWW发布了新的文献求助10
3秒前
科研助手发布了新的文献求助10
4秒前
shenkekeshen的应助被等待geduo采纳,获得10
5秒前
小六子完成签到,获得积分10
5秒前
YU发布了新的文献求助10
6秒前
卤盐完成签到,获得积分10
6秒前
隐形曼青的应助被初景采纳,获得10
7秒前
ding的应助被xiahaijun采纳,获得10
7秒前
YunJi发布了新的文献求助10
7秒前
WLJlele发布了新的文献求助10
7秒前
慕青的应助被高贵梦露采纳,获得10
8秒前
情怀的应助被鹅黄色的丹桂采纳,获得10
8秒前
9秒前
我不看月亮完成签到 ,获得积分10
9秒前
CipherSage的应助被Zhang采纳,获得10
10秒前
LuoPeng发布了新的文献求助10
10秒前
11秒前
黄佳怡完成签到 ,获得积分10
12秒前
SciGPT的应助被Mole采纳,获得10
12秒前
why完成签到,获得积分10
12秒前
nalin完成签到 ,获得积分10
12秒前
magicstool发布了新的文献求助10
14秒前
上官若男的应助被科研通管家采纳,获得10
14秒前
Crssss的应助被科研通管家采纳,获得10
14秒前
诸葛明明的应助被科研通管家采纳,获得20
14秒前
田様的应助被科研通管家采纳,获得10
15秒前
赘婿的应助被科研通管家采纳,获得10
15秒前
秋风的应助被ting采纳,获得10
15秒前
15秒前
华仔的应助被科研通管家采纳,获得10
15秒前
Hello的应助被科研通管家采纳,获得10
15秒前
loii的应助被科研通管家采纳,获得10
15秒前
搜集达人的应助被科研通管家采纳,获得10
15秒前
在水一方的应助被科研通管家采纳,获得20
16秒前
深情安青的应助被科研通管家采纳,获得10
16秒前
所所的应助被科研通管家采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189584
求助须知:如何正确求助?哪些是违规求助? 9576880
关于积分的说明 21849988
捐赠科研通 7787473
什么是DOI,文献DOI怎么找? 3435679
关于科研通互助平台的介绍 2559801
邀请新用户注册赠送积分活动 2482606